Stay updated on SAGE-718 in PD-MCI Safety & Tolerability Clinical Trial
Sign up to get notified when there's something new on the SAGE-718 in PD-MCI Safety & Tolerability Clinical Trial page.

Latest updates to the SAGE-718 in PD-MCI Safety & Tolerability Clinical Trial page
- Check2 days agoChange DetectedThe study details, eligibility criteria, and outcome measures remain unchanged, and only the page layout and header appear updated; to avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check9 days agoNo Change Detected
- Check30 days agoChange DetectedMajor update: page now includes a government funding status notice and indicates version 3.2.0, replacing the previous 3.1.0.SummaryDifference4%

- Check38 days agoChange DetectedVersion update: from v3.0.2 to v3.1.0.SummaryDifference0.1%

- Check45 days agoChange DetectedChanged company name to Supernus Pharmaceuticals, Inc. and updated last update timestamps to include 2025 dates; removed older Sage Therapeutics references and exact previous last update line.SummaryDifference2%

- Check52 days agoChange DetectedRevision: v3.0.2 has replaced v3.0.1 on the page. The 'Back to Top' link was removed.SummaryDifference0.2%

- Check59 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content.SummaryDifference0.2%

Stay in the know with updates to SAGE-718 in PD-MCI Safety & Tolerability Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SAGE-718 in PD-MCI Safety & Tolerability Clinical Trial page.